Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET

CONCLUSION: Prognostic group classifications were confirmed: PSA < 0.8 ng/mL and M1a showed a better outcome than patients with M1c and PSA ≥ 0.8 ng/mL. These results could facilitate patient selection for prospective clinical trials in OM prostate cancer.PMID:33849812 | DOI:10.1016/j.clgc.2021.03.004

Source: Clinical Prostate Cancer - April 14, 2021 Category: Cancer & Oncology Authors: Gwenaelle Gravis Aur élie Autret Morgane Guibert-Broudic Thomas Duberg é Christophe Zemmour Patricia Carrier Naji Salem Delphine Badinand Lysian Cartier Emmanuel Gross Jochen Walz G éraldine Pignot Isabelle Brenot-Rossi Source Type: research